Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy

(2011) T. Fu et al.   CANCER RESEARCH

CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans

(2011) R. R. Huang et al.   CLINICAL CANCER RESEARCH

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

(2010) A. A. Sarnaik et al.   CLINICAL CANCER RESEARCH

Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation

(2010) Kirsten M.L. Hertoghs et al.   JOURNAL OF CLINICAL INVESTIGATION

Imaging of CTLA4 Blockade-Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab

(2010) A. Ribas et al.   JOURNAL OF NUCLEAR MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma

(2010) Begoña Comin-Anduix et al.   PLoS One

Ipilimumab: controversies in its development, utility and autoimmune adverse events

(2009) Jeffrey Weber   CANCER IMMUNOLOGY IMMUNOTHERAPY

Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

(2009) A. Ribas et al.   CLINICAL CANCER RESEARCH

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

(2009) J. Weber et al.   CLINICAL CANCER RESEARCH

CTLA-4 co-receptor impacts on the function of Treg and CD8+T-cell subsets

(2009) Christopher E. Rudd   EUROPEAN JOURNAL OF IMMUNOLOGY

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

(2009) Erika von Euw et al.   Journal of Translational Medicine

Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

(2009) Hong Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

fdrtool: a versatile R package for estimating local and tail area-based false discovery rates

(2008) K. Strimmer   BIOINFORMATICS

Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade

(2008) A. Ribas et al.   CLINICAL CANCER RESEARCH

Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment

(2008) Lawrence Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells

(2008) Aurelie T Bauquet et al.   NATURE IMMUNOLOGY

CTLA-4 Activation of Phosphatidylinositol 3-Kinase (PI 3-K) and Protein Kinase B (PKB/AKT) Sustains T-Cell Anergy without Cell Death

(2008) Helga Schneider et al.   PLoS One